Rethinking Regulatory Harmonization for Advanced Therapeutics: Streamlining Global Access to Gene, Cell, and RNA-Based Medicines
  The emergence of revolutionary advanced therapeutic medicinal products (ATMPs), including gene therapies, cell therapies, and mRNA-based vaccines, has exposed significant fragmentation and inefficiency within the global regulatory landscape. These modalities, characterized by their immense complexity, patient-specific manufacturing processes, and unique risk profiles, often do not fit...
0 Σχόλια 0 Μοιράστηκε 92 Views 0 Προεπισκόπηση
Προωθημένο